NASDAQ:CLDX Celldex Therapeutics (CLDX) Stock Price, News & Analysis $19.57 -0.01 (-0.05%) Closing price 04:00 PM EasternExtended Trading$19.58 +0.01 (+0.05%) As of 04:05 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Celldex Therapeutics Stock (NASDAQ:CLDX) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Celldex Therapeutics alerts:Sign Up Key Stats Today's Range$18.91▼$19.6550-Day Range$15.13▼$23.0352-Week Range$14.40▼$47.00Volume377,561 shsAverage Volume880,655 shsMarket Capitalization$1.30 billionP/E RatioN/ADividend YieldN/APrice Target$54.33Consensus RatingModerate Buy Company OverviewCelldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases. The company's clinical development programs CDX-0159, a Phase II monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity. It has research collaboration and license agreements with Yale University. The company was incorporated in 1983 and is headquartered in Hampton, New Jersey.Read More… Celldex Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks55th Percentile Overall ScoreCLDX MarketRank™: Celldex Therapeutics scored higher than 55% of companies evaluated by MarketBeat, and ranked 539th out of 916 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.4 / 5Analyst RatingModerate Buy Consensus RatingCelldex Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.89, and is based on 6 buy ratings, 2 hold ratings, and no sell ratings.Amount of Analyst CoverageCelldex Therapeutics has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Celldex Therapeutics' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Celldex Therapeutics are expected to decrease in the coming year, from ($2.48) to ($3.34) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Celldex Therapeutics is -7.61, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Celldex Therapeutics is -7.61, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCelldex Therapeutics has a P/B Ratio of 2.16. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Celldex Therapeutics' valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted13.00% of the float of Celldex Therapeutics has been sold short.Short Interest Ratio / Days to CoverCelldex Therapeutics has a short interest ratio ("days to cover") of 9.3.Change versus previous monthShort interest in Celldex Therapeutics has recently decreased by 9.29%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldCelldex Therapeutics does not currently pay a dividend.Dividend GrowthCelldex Therapeutics does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted13.00% of the float of Celldex Therapeutics has been sold short.Short Interest Ratio / Days to CoverCelldex Therapeutics has a short interest ratio ("days to cover") of 9.3.Change versus previous monthShort interest in Celldex Therapeutics has recently decreased by 9.29%, indicating that investor sentiment is improving significantly. News and Social Media3.4 / 5News Sentiment1.12 News SentimentCelldex Therapeutics has a news sentiment score of 1.12. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.74 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 7 news articles for Celldex Therapeutics this week, compared to 4 articles on an average week.MarketBeat Follows1 people have added Celldex Therapeutics to their MarketBeat watchlist in the last 30 days. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Celldex Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 3.80% of the stock of Celldex Therapeutics is held by insiders.Read more about Celldex Therapeutics' insider trading history. Receive CLDX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Celldex Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address CLDX Stock News HeadlinesCommit To Purchase Celldex Therapeutics At $15, Earn 20.1% Annualized Using OptionsApril 23 at 9:49 AM | nasdaq.comCelldex initiated with an Overweight at Morgan StanleyMarch 21, 2025 | markets.businessinsider.comNew “Trump” currency proposed in DCAccording to one of the most connected men in Washington… A surprising new bill was just introduced in Washington. Its purpose: to put Donald Trump’s face on the $100 note. All to celebrate a new “golden age” for America. April 25, 2025 | Paradigm Press (Ad)Morgan Stanley Initiates Coverage of Celldex Therapeutics (CLDX) with Overweight RecommendationMarch 21, 2025 | msn.com3CLDX : 7 Analysts Have This To Say About Celldex TherapeuticsMarch 21, 2025 | benzinga.comCelldex presents preclinical data from CDX-622 at AAAAI 2025March 4, 2025 | markets.businessinsider.comCelldex Therapeutics to Present at Upcoming Investor ConferencesMarch 4, 2025 | globenewswire.comCelldex Therapeutics Inc (CLDX) Announces Promising Preclinical Data for CDX-622March 3, 2025 | gurufocus.comSee More Headlines CLDX Stock Analysis - Frequently Asked Questions How have CLDX shares performed this year? Celldex Therapeutics' stock was trading at $25.27 on January 1st, 2025. Since then, CLDX shares have decreased by 22.6% and is now trading at $19.57. View the best growth stocks for 2025 here. How were Celldex Therapeutics' earnings last quarter? Celldex Therapeutics, Inc. (NASDAQ:CLDX) issued its quarterly earnings results on Thursday, February, 27th. The biopharmaceutical company reported ($0.71) EPS for the quarter, beating analysts' consensus estimates of ($0.73) by $0.02. The biopharmaceutical company earned $1.18 million during the quarter, compared to the consensus estimate of $1.25 million. Celldex Therapeutics had a negative trailing twelve-month return on equity of 19.75% and a negative net margin of 1,544.32%. When did Celldex Therapeutics' stock split? Shares of Celldex Therapeutics reverse split before market open on Monday, February 11th 2019. The 1-15 reverse split was announced on Friday, February 8th 2019. The number of shares owned by shareholders was adjusted after the closing bell on Friday, February 8th 2019. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split. Who are Celldex Therapeutics' major shareholders? Top institutional shareholders of Celldex Therapeutics include Mirador Capital Partners LP (0.19%), Rhumbline Advisers (0.15%), SG Americas Securities LLC (0.05%) and Apella Capital LLC (0.03%). Insiders that own company stock include Anthony S Marucci, Samuel Bates Martin, Richard M Wright, Elizabeth Crowley, Margo Heath-Chiozzi, Diane C Young and Sarah Cavanaugh. View institutional ownership trends. How do I buy shares of Celldex Therapeutics? Shares of CLDX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Celldex Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Celldex Therapeutics investors own include Meta Platforms (META), Advanced Micro Devices (AMD), NVIDIA (NVDA), Tesla (TSLA), Netflix (NFLX), Alphabet (GOOG) and Visa (V). Company Calendar Last Earnings2/27/2025Today4/25/2025Next Earnings (Estimated)5/05/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Diagnostic substances Sub-IndustryBiotechnology Current SymbolNASDAQ:CLDX CIK744218 Webwww.celldex.com Phone(908) 454-7120Fax908-454-1911Employees150Year Founded1983Price Target and Rating Average Stock Price Target$54.33 High Stock Price Target$80.00 Low Stock Price Target$36.00 Potential Upside/Downside+177.6%Consensus RatingModerate Buy Rating Score (0-4)2.89 Research Coverage9 Analysts Profitability EPS (Most Recent Fiscal Year)($2.45) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-141,430,000.00 Net Margins-1,544.32% Pretax Margin-1,544.32% Return on Equity-19.75% Return on Assets-18.86% Debt Debt-to-Equity RatioN/A Current Ratio24.27 Quick Ratio24.27 Sales & Book Value Annual Sales$7.02 million Price / Sales185.06 Cash FlowN/A Price / Cash FlowN/A Book Value$9.08 per share Price / Book2.16Miscellaneous Outstanding Shares66,384,000Free Float63,823,000Market Cap$1.30 billion OptionableOptionable Beta1.59 Social Links A Beginner's Guide to Investing in CannabisUnlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.Get This Free Report This page (NASDAQ:CLDX) was last updated on 4/25/2025 by MarketBeat.com Staff From Our PartnersElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored"I'm risking my reputation on this"I've discovered something so significant about the 2025 crypto market that I had to put everything else aside ...Crypto 101 Media | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowMy friends Joel and Adam have a simple motto: "For us, it's always a bull market." That’s because their 92%...Crypto Swap Profits | SponsoredSecret financial plot unfolding in Washington DC… [DEVELOPING]What stocks are next up to soar in 2025? I believe I’ve found the answer - and it might surprise you. Yo...Timothy Sykes | SponsoredTrump purposefully forcing markets to crash…Whether you agree with the plan or not doesn’t matter. It’s happening. The only question is – are you re...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Celldex Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Celldex Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.